Abstract library

63 results for "robot-assisted pancreatectomy".
#235 Robot-assisted Distal Pancreatectomy for Insulinoma. A Case Report
Introduction: A literature review on laparoscopic pancreatic resection was conducted with emphasis on its applicability and safety. The outcome of the procedures for pancreatic insulinoma is similar to open surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Alexander Vladimir Kochatkov
#1214 Initial Experience with Robot-Assisted Distal Pancreatectomy for Pancreatic Neuroendocrine Neoplasms
Introduction: Robot-assisted distal pancreatectomy (RADP) for pancreatic neuroendocrine neoplasms (pNEN) has not been investigated so far
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Stefano Partelli
#58 Surgical approaches in 84 patients with insulinomas in multiple endocrine neoplasia type 1 (MEN 1)
Introduction: Management of insulinomas in the setting of Multiple Endocrine Neoplasia type 1 (MEN1) remains controversial.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Delphine Vezzosi
#520 Left Pancreatectomy for Neuroendocrine Pancreatic Tumors
Introduction: Distal pancreatectomy for neuroendocrine tumors localized in the body-tail of the pancreas (NTP) can be performed either with splenectomy (DP) or with a spleen-preserving procedure (SPLP).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Claudio Pasquali
#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?
Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Chiappa A, ...
#1092 Experience of Two European Centers on Central Pancreatectomy for NeuroEndocrine Tumors of the Pancreas
Introduction: Central pancreatectomy (CP) is a parenchima-sparing operation that enables the removal of benign or low-grade malignant lesions from the neck of the pancreas.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Doctor Valbona Lico
#630 Pancreatic Polypeptide Cell Hyperplasia Associated with Nonfunctioning Pancreatic Neuroendocrine Tumor: A Case Report
Introduction: A case report of pancreatic polypeptide (PP) cell hyperplasia in association with nonfunctioning pancreatic neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Aleksandar Prazic
#774 The Grading of pNENs in MEN-1 Syndrome: Consequences for Tumor Progression and Surgical Strategy?
Introduction: MEN-1 patients develop multiple pNENs. The treatment of choice ranges from watchful waiting to total pancreatectomy. Up to now, the impact of the grading has not been evaluated to either plan surgery or conservative treatment.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Andreas Selberherr
Keywords: MEN-1, pancreas, pNEN
#1769 Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study
Introduction: Current literature states that 15-30% of the MEN1 patients suffer from hypoglycemia after insulinoma surgery.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Keywords: MEN1
#37 Gastric GIST with synchronous neuroendocrine tumor of the pancreas, Case Report and Literature Review
Introduction: The Gastrointestinal Stromal Tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. These are rare tumors with an incidence of 15 new cases per million per year. They often occur in individuals over the age of 40 years, without gender predominance. The clinical behavior is variable and benign tumors are the most common. They can develop anywhere in the GI tract, but are more frequent in the stomach and small intestine. The primary treatment, when located, is the surgical resection, which can be complemented with the use of imatinib.
The occurrence of neuroendocrine tumors of the pancreas is rare, representing 1-5% of pancreatic cancers, and it is estimated that its incidence does not exceed 5 to one million. The tumors considered nonfunctioning (15-32% of pancreatic neuroendocrine tumors) are not associated with any syndrome, and are usually incidental. They have a slight predominance in males, and are more frequent in the 6th decade of life. Nonfunctioning tumors of islet cells are virtually all malignant tumors, and the treatment consists of surgical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dra Amelia B Tavares
Close
Notice
Important Notice:

In preparation of the upcoming 16th Annual ENETS Conference, 6 to 8 March 2019 in Barcelona, Spain, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2019 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.